R&D Center of Skin Science and Cosmetics, Enprani Co. Ltd., Incheon, South Korea.
Int J Dermatol. 2012 Jun;51(6):733-41. doi: 10.1111/j.1365-4632.2011.05332.x.
Retinoids have been used for the treatment of skin disorders such as acne, psoriasis, and photoaging. However, despite their beneficial effects, topical retinoids often cause severe local irritation called retinoid dermatitis. We previously developed a novel vitamin A derivative, retinyl retinoate, which induces less irritation and affords excellent tolerance. In this study, we examined whether co-treatment with topical peroxisome proliferator-activated receptor-α (PPARα) agonists (e.g. WY14643) reduce retinoid dermatitis in hairless mouse skin.
The effect of concomitant treatment with a PPARα agonist on retinoid dermatitis in hairless mouse epidermis was evaluated by measuring transepidermal water loss, epidermal histology, and cytokine expression.
Retinyl retinoate induced less severe retinoid dermatitis than retinoic acid. Topical application of a PPARα agonist improved the stratum corneum structure and function, reduced mRNA expression of interleukin (IL)-1α, tumor necrosis factor-α and IL-8, and inhibited ear edema induced by retinoic acid or retinyl retinoate.
Our results indicate that PPARα agonists can potentially be used to improve retinoid dermatitis. We suggest that co-treatment with retinyl retinoate and a PPARα agonist may reduce or prevent detrimental alterations in retinoid-treated skin.
类视黄醇已被用于治疗皮肤疾病，如痤疮、银屑病和光老化。然而，尽管它们有有益的效果，局部类视黄醇往往会引起严重的局部刺激，称为类视黄醇皮炎。我们之前开发了一种新型维生素 A 衍生物，视黄基视黄醇酯，它引起的刺激较小，具有良好的耐受性。在这项研究中，我们研究了局部过氧化物酶体增殖物激活受体-α（PPARα）激动剂（如 WY14643）的共同治疗是否能减少无毛鼠皮肤中的类视黄醇皮炎。
通过测量经表皮水分流失、表皮组织学和细胞因子表达，评估 PPARα 激动剂同时治疗对无毛鼠表皮类视黄醇皮炎的影响。
视黄基视黄醇酯引起的类视黄醇皮炎比视黄酸轻。局部应用 PPARα 激动剂改善了角质层结构和功能，降低了白细胞介素（IL）-1α、肿瘤坏死因子-α和 IL-8 的 mRNA 表达，并抑制了视黄酸或视黄基视黄醇酯引起的耳肿胀。
我们的结果表明，PPARα 激动剂可能可用于改善类视黄醇皮炎。我们建议，视黄基视黄醇酯和 PPARα 激动剂的共同治疗可能会减少或预防类视黄醇治疗皮肤的有害改变。
